title: Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective.
abstract: Recently, novel anti-androgens and inhibitors of androgen biosynthesis have been developed through the elucidation of mechanisms of castration resistance of prostate cancer. We believe that these new developments will improve hormonal therapy. On the other hand, there has been an increase in criticism of hormonal therapy, because hormonal therapy is supposed to induce adverse effects such as cardiovascular disease. In this review, we have introduced the Japanese experience of hormonal therapy, because we believe that there may be ethnic differences between Caucasians and Asian people in the efficacy and adverse effects of hormonal therapy. First, we showed that primary hormonal therapy can achieve long-term control of localized prostate cancer in some cases and that quality of life of patients receiving hormonal therapy is rather better than previously thought. Neoadjuvant and adjuvant hormonal therapy in cases undergoing radical prostatectomy or radiotherapy are very useful for high-risk or locally advanced prostate cancer. Further clinical trials are required to confirm the efficacy of neoadjuvant or adjuvant hormonal therapy. We showed that the death from cardiovascular diseases in Japanese patients receiving hormonal therapy was not higher than that in the general population. However, efforts should be made to decrease the adverse effects of hormonal therapy, because life-style change may increase the susceptibility to adverse effects by hormonal therapy even in Japan. Managements of endocrine and metabolic dysfunction, such as diabetes mellitus, are essential. New hormonal compounds such as selective androgen receptor modulators capable of specifically targeting prostate cancer are expected to be developed.
authors.affiliation: Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. namiki1@kenroku.kanazawa-u.ac.jp
authors.forename: Mikio
authors.initials: M
authors.lastname: Namiki
authors.forename: Satoru
authors.initials: S
authors.lastname: Ueno
authors.forename: Yasuhide
authors.initials: Y
authors.lastname: Kitagawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Fukagai
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Akaza
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D044466:Asian People / Q000208:ethnology; D003131:Combined Modality Therapy; D006254:Hawaii / Q000208:ethnology; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics; D011944:Receptors, Androgen / Q000187:drug effects; D015996:Survival Rate; D016896:Treatment Outcome; D044465:White People / Q000208:ethnology
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D011944:Receptors, Androgen